The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial

Diabetes Obes Metab. 2022 Aug;24(8):1638-1642. doi: 10.1111/dom.14717. Epub 2022 May 12.

Authors

Suvanjaa Sivalingam¹, Emilie Hein Zobel¹, Christian S Hansen¹, Rasmus S Ripa^{2

3}, Bernt J von Scholten^{1

4}, Viktor Rotbain Curovic¹, Andreas Kjaer^{2

3}, Jacob K Jensen², Tine W Hansen¹, Peter Rossing^{1

3}

Affiliations

¹ Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
² Department of Clinical Physiology and Nuclear Medicine and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
³ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
⁴ Novo Nordisk A/S, Søborg, Denmark.

PMID: 35415938
DOI: 10.1111/dom.14717

No abstract available

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Double-Blind Method
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Liraglutide* / pharmacology
Liraglutide* / therapeutic use
Stroke Volume
Treatment Outcome

Substances

Hypoglycemic Agents
Liraglutide